在HFrEF患者中,指导方针导向的医疗疗诱导了毒性;对其机制的洞察
Anu Philip1, Prarambh S R Dwivedi2, C S Shastry1
1Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Mangalore, India.
Journal of biomolecular structure & dynamics
|March 11, 2024
概括
心力衰竭的指导导医疗疗法 (GDMT) 可能会导致脏损伤. 这项研究使用系统生物学来识别特定的药物组合和分子标,如HBA1和CBR1,与潜在的毒性有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
- 计算生物学 计算生物学
- 系统生物学 系统生物学
背景情况:
- 准则定向医疗疗法 (GDMT) 是用于心力衰竭的标准药物治疗,其减少的喷射分数 (HFrEF).
- 欧洲心脏病学会 (ESC) 的指导方针建议使用特定的GDMT组合.
- 毒性是GDMT在HFrEF患者中的潜在不良影响.
研究的目的:
- 预测GDMT诱导的毒性背后的分子机制.
- 确定特定的GDMT药物组合和与毒性相关的分子标.
主要方法:
- 利用系统生物学工具,包括ADVER-Pred,基因丰富分析,分子对接和分子动态模拟.
- 根据ACC/AHA/ESC指南将GDMT分为三组.
- 分析了蛋白质-蛋白质相互作用网络,以确定枢纽基因和结合亲缘关系.
主要成果:
- 基因丰富分析表明,2类药物 (β阻断剂,SGLT2抑制剂,ARNI) 与毒性 (79.41%) 的相关性最高.
- 发现的顶级枢纽基因包括HBA1,CBR1,ATG5和SLC6A3.3.
- 分子对接揭示了坎德沙坦和SLC6A3 (-10.2 kcal/mol) 之间的高结合亲和力,分子动力学模拟显示了empagliflozin-CBR1和坎德沙坦-ATG5相互作用的稳定性.
结论:
- 结合β-阻断剂, ангиотензин受体阻断剂 (ARBs) 和-葡萄糖转运体-2 抑制剂 (SGLT2I) 可能导致毒性.
- 已识别的分子标 (HBA1,CBR1,ATG5,GPX1) 与毒性影响有关.
- 预计坎德沙坦和恩帕格利弗洛辛是通过调节这些特定基因而导致毒性的最可能的罪祸首.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:22Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625